AUS
NZ
UK
CA
USA
IND
Healthcare
Singular Health Group Expands Market Footprint with New ASX Securities Listing
June 26, 2025 10:20 AM AEST| By Team Kalkine MediaHighlights,Singular Health Group adds 1.57 million new securities to ASX,Move supports strategic capital flexibility and expansion goals,Focus,remains,on digital innovation in medical imaging,Singular Health Group Ltd (ASX:SHG), a digital healthcare...
Why Sonic Healthcare (ASX:SHL) Is Still in the Spotlight on the ASX300
June 25, 2025 10:46 AM AEST| By Team Kalkine MediaHighlights,SHL shares reflect solid healthcare fundamentals,Sector supported by resilient demand trends,Valuation appears below historical average,The share price of Sonic Healthcare Ltd (ASX:SHL) has seen a modest decline of 4.2% since the beginning...
Biotron (ASX:BIT) Advances Hepatitis B Therapy with Positive Safety Milestone
June 24, 2025 04:07 PM AEST| By Team Kalkine MediaHighlights,Biotron completes initial safety trials for HBV therapy,Antiviral testing in preclinical models set to begin,Progress backed by recent funding round,Biotron (ASX:BIT), a clinical-stage biotechnology company, has achieved a significant mile...
Tryptamine Therapeutics Secures Ethics Approval for Psilocin BED Trial | ASX 200
June 23, 2025 02:43 PM AEST| By Team Kalkine MediaHighlights,Tryptamine Therapeutics gains approval to commence first-in-human trial for BED using TRP-8803,Study to assess safety and impact on BED and related psychiatric conditions,Patient recruitment underway with treatment scheduled to begin later...
Neurizon Therapeutics Unveils Promising Preclinical Findings for ALS Therapy
June 20, 2025 06:09 PM AEST| By Team Kalkine MediaHighlights,NUZ-001 shows promising blood-brain barrier penetration.,Strong preclinical evidence supports ALS treatment potential.,Reinforces Neurizon’s position in innovative neurological therapeutics.,Neurizon Therapeutics (ASX:NUZ) has taken a sign...
CSL Gains FDA Nod as ASX 200 Healthcare Faces Global Pressure
June 20, 2025 05:21 PM AEST| By Team Kalkine MediaHighlights,CSL Limited (ASX:CSL) receives FDA clearance for rare disease treatment,Healthcare stocks within the ASX 200 and ASX 100 indices reflect cautious sentiment,External trade and policy developments influence ASX 200 healthcare performance,CSL...
Orthocell’s Breakthrough in Nerve Repair Places It on the ASX200 Innovation Radar
June 20, 2025 03:40 PM AEST| By Team Kalkine MediaHighlights,Orthocell’s Remplir outperforms traditional suture-only nerve repair methods,Interim study results support rapid U.S. product rollout,Potential to impact ASX200 medical innovation landscape,Orthocell (ASX:OCC) has unveiled encouraging inte...
ECS Botanics (ASX:ECS) Faces Pressure Amid Revenue Concerns | All Ordinaries Spotlight
June 20, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,ECS Botanics Holdings Ltd shares decline amid shrinking revenue performance,Valuation metrics reflect subdued expectations compared to pharmaceutical peers,Broader All Ordinaries index maintains contrast with ECS’s sectoral challenges,ECS...
Arovella Therapeutics Extends Momentum on ASX 200 with Continued Growth Streak
June 20, 2025 02:46 PM AEST| By Team Kalkine MediaHighlights,Arovella Therapeutics continues gaining traction within the healthcare segment,Long-term revenue trend aligns with rising shareholder interest,Company performance draws attention across,ASX 200,and,All Ordinaries,indices,Arovella Therapeut...
Ramsay Health Care Faces Extended Downtrend | ASX 50 Healthcare Stock Performance Dips
June 20, 2025 02:40 PM AEST| By Team Kalkine MediaHighlights,Ramsay Health Care's earnings per share experienced extended contraction over recent years,Long-term share performance remained below broader market benchmarks,Dividends have offset some value loss, contributing to higher total shareholder...
Neurizon Therapeutics Unveils Promising Platform Therapy Potential for ALS and HD, Strengthening ASX200 Biotech Profile
June 20, 2025 11:50 AM AEST| By Team Kalkine MediaHighlights,NUZ-001 shows strong brain penetration in ALS and HD models,Promising neuroprotective effects,demonstrated,in multiple preclinical studies,Platform potential for broader neurodegenerative disorders,Neurizon Therapeutics (ASX:NUZ), a clinic...
Race Oncology (ASX:RAC) Launches First Patient Dosing in RC220 Trial
June 20, 2025 10:51 AM AEST| By Team Kalkine MediaHighlights,RC220 and doxorubicin combination enters Phase 1,No serious toxicities seen in,initial,patient,Expansion planned into Asia, US, and Europe,Race Oncology (ASX:RAC),has marked a pivotal moment in its drug development journey with the success...
Clarity Pharmaceuticals (ASX:CU6) Advances U.S. Manufacturing in ASX 300 Healthcare Sector
June 19, 2025 06:58 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (ASX:CU6) belongs to the ASX 300 and operates within the healthcare sector focused on radiopharmaceuticals,Recent manufacturing agreement with SpectronRX supports U.S. readiness for cancer imaging product developmen...
Promising Start for Race Oncology’s RC220 Trial Among ASX200 Developments
June 19, 2025 05:57 PM AEST| By Team Kalkine MediaHighlights,First patient safely dosed with RC220 and doxorubicin,Trial expands across Australia, Hong Kong, and South Korea,Early safety data supports future development milestones,Race Oncology (ASX:RAC),has marked a significant clinical milestone w...
Singular Health (ASX:SHG) Advances US Market Reach with Strategic PNS Deal and Capital Raise
June 19, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,Singular Health (SHG) inks a $2 million deal to expand its 3D medical imaging platform in the US,Secures $8 million strategic placement to fund expansion and innovation,Partnership with US-based PNS aims to tackle systemic healthcare ineff...
Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update
June 19, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,Formycon AG shareholders approve all agenda items at its annual general meeting,Supervisory Board expanded with re-election of Klaus Röhrig and appointment of Dr. Graham Dixon,Management outlines strategic vision for biosimilar market deve...
Orthocell's Remplir Delivers Breakthrough in Nerve Repair, Strengthening Global Ambitions
June 19, 2025 02:32 PM AEST| By Team Kalkine MediaHighlights,Remplir outperforms traditional nerve repair methods,Orthocell’s US market entry gains momentum,Global expansion continues with strong regulatory support,Orthocell Ltd (ASX:OCC) has reported highly encouraging interim results from a pivota...
Neuren Pharmaceuticals (ASX:NEU) Shows Strong Metrics Despite Market Pullback | ASX 300
June 19, 2025 02:28 PM AEST| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals continues to display robust return on equity within the healthcare sector,Earnings growth remains high compared to broader industry benchmarks,Retained profits signal reinvestment into operations for long-term develo...
Race Oncology Hits Key Milestone in RC220 Clinical Trial
June 19, 2025 02:06 PM AEST| By Team Kalkine MediaHighlights,First patient dosed with RC220 + doxorubicin in Phase 1 trial,Trial targets reduced cardiotoxicity in advanced solid tumours,Global sites and strong preclinical backing boost momentum,Race Oncology (ASX:RAC) has reached a major clinical de...
ASX200 Biotech Breakthrough: Amplia (ASX:ATX) Achieves Rare Success in Pancreatic Cancer Trial
June 19, 2025 01:16 PM AEST| By Team Kalkine MediaHighlights,Amplia,Therapeutics reports second complete response in pancreatic cancer trial,Narmafotinib,shows rare efficacy in advanced stage cases,Encouraging progress for ASX-listed biotech in high-mortality cancer treatment,Amplia Therapeutics (AS...
Advertise your brand on Kalkine Media